COMMUNIQUÉS West-GlobeNewswire

Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)
24/06/2025
Good Tolerability and Robust Tumor Uptake were Observed in TNBC Animal Models Auger Emitters Offer the Potential Benefit of Enhanced Cytotoxicity, Safety and Ease-of-Use FLORHAM PARK, N.J., June 24, 2025 (GLOBE NEWSWIRE [...]
Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement
24/06/2025
Stockholder-approved financing brings total gross proceeds to $7.1 million; funds to support working capital initiatives CAMBRIDGE, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing [...]
THC Therapeutics, Inc. Announces Acquisition of Oregon and California Consortium of Cannabis Companies
24/06/2025
Breakthrough Transaction Unites Segment Leaders into a Powerful and Flexible Player in the Legal Cannabis Industry MEDFORD, Ore., June 24, 2025 (GLOBE NEWSWIRE) -- THC Therapeutics, Inc. (“THCT” or the “Company”), (OTC [...]
Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation
24/06/2025
--During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study; on average, [...]
CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer
24/06/2025
Enrollment is now underway across multiple clinical sites, in partnership with Syneos Health VANCOUVER, Washington, June 24, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a [...]
Xenon Announces Appointment of Darren Cline as Chief Commercial Officer
24/06/2025
Mr. Cline brings extensive commercial expertise to lead the transition of Xenon to a commercial-stage company with the anticipated launch of azetukalner across three potential indications VANCOUVER, British Columbia and [...]
Journey Medical to Join Russell 2000® and Russell 3000® Indexes
24/06/2025
SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or the “Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on [...]
Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference
24/06/2025
SOUTH SAN FRANCISCO, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene [...]
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
24/06/2025
FDA has indicated that an Advisory Committee meeting is not required at this time In-person late-cycle review meeting scheduled for mid-July Biologics License Application (BLA) remains under Priority Review with PDUFA [...]
CareMore Health Announces Appointment of Sam Wald as Chief Executive Officer
24/06/2025
Wald’s history of successfully leading outcomes-focused healthcare organizations aligns with CareMore Health’s provider support and patient care priorities CERRITOS, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- CareMore [...]
Green Tree Pediatrics is Now Part of the Zarminali Pediatrics, Signaling New Chapter of Care and Community Commitment
24/06/2025
Dr. Scott Moore and his Michigan-based team have joined the national pediatric health group to expand offerings to families in the community ANN ARBOR, Mich., June 24, 2025 (GLOBE NEWSWIRE) -- Zarminali Pediatrics , the [...]
Priothera Secures €1.7 million i-Nov Funding by Bpifrance for Rare Blood Cancer Clinical Program
24/06/2025
Priothera Secures €1.7 million i-Nov Funding by Bpifrance for Rare Blood Cancer Clinical Program Funding to support MOCART, a clinical programme evaluating mocravimod added to standard CAR-T cell therapy Saint-Louis, [...]
Vivoryon Therapeutics N.V. Reports Outcome of 2025 Annual General Meeting
24/06/2025
Vivoryon Therapeutics N.V. Reports Outcome of 2025 Annual General Meeting Halle (Saale) / Munich, Germany, June 24 , 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical [...]
Celia Huber Joins AMN Healthcare Board of Directors
24/06/2025
Huber brings more than 30 years of experience across multiple sectors DALLAS, June 24, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations [...]
Innovate GBM Rings the NASDAQ Closing Bell in Honor of Brain Tumor Patients and Community
24/06/2025
LOS ANGELES, June 24, 2025 (GLOBE NEWSWIRE) -- Innovate GBM, a 501(c)(3) nonprofit organization dedicated to transforming the future of brain tumor research and treatment through collaboration, infrastructure, and [...]
SeaStar Medical Announces Two Feature Stories on QUELIMMUNE Adoption and Patient Testimonial of Life-Saving Therapy
24/06/2025
Cincinnati Children’s Hospital Medical Center Discusses QUELIMMUNE Therapy Adoption A Father and Patient Describe Their Real-Life Experience with the QUELIMMUNE Therapy DENVER, June 24, 2025 (GLOBE NEWSWIRE) -- SeaStar [...]
Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock
24/06/2025
NEEDHAM, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
Progyny Adds Pelvic Floor Therapy, Continuing to Close Gaps in Care Across Women’s Health
24/06/2025
With nearly one third of women impacted by pelvic floor disorders, expanded care access and education from Progyny will help eliminate the silent suffering NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Progyny , Inc. ( [...]
Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial
24/06/2025
- Near doubling of 1-year overall survival (OS), increased median OS of 4 months (12.5 vs 8.5 months), and 43% reduction in risk of death in patients treated with at least one cycle (4 weeks) of elraglusib plus [...]

Pages